comparemela.com

Latest Breaking News On - Julia hofmann susanne karlsson - Page 1 : comparemela.com

ITM Isotope Technologies Munich SE: ITM Signs Clinical Supply Agreement with Y-mAbs for n c a Lutetium-177

ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs' Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive solid

Valeria fisherBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaCorporate communicationsY mabs therapeutics incTrophic communicationsDeutsche bank freiburgPharma solutions gmbY mab targeted radionuclide therapyTechnologies munichY mabs therapeuticsTargeted radionuclide therapyRadionuclide therapyBank freiburg

Investegate |ITM Isotope Technologies Munic Announcements | ITM Isotope Technologies Munic: ITM Signs Clinical Supply Agreement with Y-mAbs for n c a Lutetium-177

Investegate announcements from ITM Isotope Technologies Munic, ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177

Valeria fisherBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaUdoj vetterCorporate communicationsY mabs therapeutics incDistrict courtTrophic communicationsDeutsche bank freiburgPharma solutions gmbClinical supply agreementY mab targeted radionuclide therapyTechnologies munichY mabs therapeutics

ITM Signs Clinical Supply Agreement with Y-mAbs for n c a Lutetium-177

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Valeria fisherBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaUdoj vetterCorporate communicationsY mabs therapeutics incDistrict courtTrophic communicationsDeutsche bank freiburgPharma solutions gmbY mab targeted radionuclide therapyTechnologies munichY mabs therapeuticsTargeted radionuclide therapy

ITM and MTTI Sign Clinical Supply Agreement for n c a Lutetium-177

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative

Kostenloser wertpapierhandelBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaChris pakMolecular targeting technologies incCorporate communicationsTechnologies munichMolecular targeting technologiesTargeted radionuclide therapyTargeted radionuclide therapiesRadionuclide therapyTargeting technologies

Molecular Targeting Technologies Inc (MTTI): MTTI and ITM Sign Clinical Supply Agreement for n c a Lutetium-177

Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical

Kostenloser wertpapierhandelBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaChris pakMolecular targeting technologies incCorporate communicationsMolecular targeting technologiesTechnologies munichTargeted radionuclide therapyTargeted radionuclide therapiesRadionuclide therapyTargeting technologiesHofmann susanne karlsson

vimarsana © 2020. All Rights Reserved.